Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation
Par previously sued Eagle in 2018, alleging infringement of several of its patents and a trial was held in July 2021.
- Par previously sued Eagle in 2018, alleging infringement of several of its patents and a trial was held in July 2021.
- The District Court held that Eagle did not infringe on any of Pars patents, and Par appealed.
- Oral arguments were held before the Federal Circuit in July 2022.
- Today, the Federal Circuit issued its decision rejecting Pars arguments and affirming the District Courts finding of non-infringement.